Hympavzi

HYMPAVZI is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with:

• •hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors, or
• •hemophilia B (congenital factor IX deficiency) without factor IX inhibitors.

HYMPAVZI (marstacimab‑hncq) is a clear and colorless to light yellow solution available as:

Prefilled Syringe

• •Injection: 150 mg/mL in a single-dose prefilled syringe

Prefilled Pen

• •Injection: 150 mg/mL in a single-dose prefilled pen